Pharma Marketing Network

DECEMBER 31, 2024

Table of Contents Sr# Headings 1 Introduction: The Pharma Marketing Challenge 2 Building a Winning Pharma Marketing Strategy 3 The Role of Branded Drug Campaigns 4 Innovating for Future Success Introduction: The Pharma Marketing Challenge Marketing pharmaceuticals is no small feat. In an industry where lives are at stake, creating compelling, compliant, and effective campaigns can feel like walking a tightrope.

Marketing 52

Marketing Branding Compliance Drugs 52

Pharmaceutical Technology

JANUARY 2, 2025

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.

162

162

Bio Pharma Dive

JANUARY 2, 2025

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.

Clinical Trials 272

Clinical Trials Clinical Trials Trials 272

Drug Patent Watch

DECEMBER 30, 2024

The regulatory environment in Japan for generic drug development is complex and has undergone significant changes in recent years. This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market.

Generic Drugs 52

Generic Drugs Bioequivalency Development Drugs 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

XTalks

DECEMBER 31, 2024

Hansa Biopharma has announced positive complete results from its single arm 15-HMedIdeS-09 Phase II study on the use of imlifidase for the treatment of the rare disease Guillain-Barr syndrome (GBS). The company conducted an indirect treatment comparison analysis of 15-HMedIdeS-09 study data to the International Guillain-Barr Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.

Life Science 52

Life Science Clinical Trials Clinical Trials Antibody 52

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 29, 2024

(Dave & Les Jacobs/DigitalVision/Getty Images) We know that too much sitting is bad for us, but a new study adds an important detail: if you spend more than 10-and-a-half hours a day sitting or lying down, regular exercise might not be enough to prevent an increased risk of serious heart issues.

Clinical Trials 193

Clinical Trials Clinical Trials Trials 193

Pharmaceutical Commerce

DECEMBER 31, 2024

Pharma Commerce was on the road extensively throughout 2024, and plenty of insight was gathered along the way.

52

52

pharmaphorum

DECEMBER 31, 2024

Sangamo is 'surprised and disappointed' by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results

Gene Therapy 105

Gene Therapy Gene 105

pharmaphorum

DECEMBER 30, 2024

Learn how digital biomarkers are revolutionising respiratory care by providing personalised, real-time data for better monitoring and management of respiratory diseases.

65

65

Pharmaceutical Technology

JANUARY 2, 2025

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Marketing 255

Marketing 255

Advertisement

Clinical Supply

Bio Pharma Dive

JANUARY 2, 2025

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.

Drugs 167

Drugs Trials 167

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 1, 2025

The Central Drugs Standard Control Organisation (CDSCO) has sought the industry to start submitting the applications for clinical trial site addition and change of principal investigator through online mode, as part of streamlining the regulatory submission procedure.

Clinical Trials 138

Clinical Trials Clinical Trials Trials Drugs 138

XTalks

JANUARY 2, 2025

Anteris Technologies Global Corp. (ATGC) has gone public with its initial public offering (IPO), marking a significant milestone in its journey to transform the heart valve market. The company offered 14.8 million shares of its common stock at an initial price of $6.00 per share. Trading began on the Nasdaq Global Market on December 13, 2024, under the ticker symbol “AVR,” with the offering closed on December 16, 2024.

FDA Approval 105

FDA Approval Marketing Clinical Trials Clinical Trials 105

Pharmaceutical Technology

JANUARY 3, 2025

The Indian Institute of Technology (IIT) Guwahati and the Bose Institute Kolkata research team have developed an advanced injectable hydrogel

Development 162

Development Research 162

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Bio Pharma Dive

JANUARY 2, 2025

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end of recent annual tallies.

FDA Approval 157

FDA Approval Drugs Medicine 157

Pharma Times

JANUARY 2, 2025

New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

117

117

Medical Xpress

JANUARY 3, 2025

University of Arizona researchers have revealed new insights into one of the most common complications faced by Parkinson's disease patients: uncontrollable movements that develop after years of treatment.

Development 106

Development Research 106

Pharmaceutical Technology

JANUARY 3, 2025

Distinguishing the stages of fibrosis in MASH is a pressing need for diagnoses and clinical trials.

Clinical Trials 147

Clinical Trials Clinical Trials Trials 147

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Bio Pharma Dive

JANUARY 2, 2025

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.

Gene Therapy 157

Gene Therapy Gene 157

Pharma Times

JANUARY 3, 2025

FDA gives green light to innovative device for liver conditions

FDA Approval 107

FDA Approval 107

pharmaphorum

JANUARY 3, 2025

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

105

105

Pharmaceutical Technology

JANUARY 3, 2025

SIGA Technologies has gained the Japanese regulatory approval for TEPOXX (tecovirimat) for the treatment of smallpox, mpox and cowpox.

147

147

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

Clinical Research

Medical Xpress

JANUARY 3, 2025

A new study from Vanderbilt University Medical Center shows that clinical alerts driven by artificial intelligence (AI) can help doctors identify patients at risk for suicide, potentially improving prevention efforts in routine medical settings.

Doctors 102

Doctors Doctor 102

Pharma Times

JANUARY 2, 2025

MHRA urges caution over illegal medicines from beauty salons and social media

Medicine 109

Medicine Regulation 109

pharmaphorum

JANUARY 3, 2025

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

FDA Approval 105

FDA Approval 105

Pharmaceutical Technology

JANUARY 3, 2025

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Marketing 147

Marketing Development 147

Advertiser: FourKites

A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.

Research

Medical Xpress

JANUARY 3, 2025

The COVID-19 pandemic highlighted how crucial testing is for disease preparedness and response, and new research from the Johns Hopkins Applied Physics Laboratory (APL) and a team of collaborators underscores that principle.

Research 100

Research 100

Pharma Times

JANUARY 3, 2025

Government announces independent commission on social care

103

103

pharmaphorum

JANUARY 2, 2025

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

105

105

Pharmaceutical Technology

JANUARY 3, 2025

China NMPA has granted acceptance and priority review for the NDA for HUTCHMEDs ORPATHYS (savolitinib) and TAGRISSO (osimertinib) combination

147

147

Advertisement

Clinical Supply